Click Here to Register »

2017 Agenda

  • 7:30 am

  • Registration & Breakfast

  • 8:15 am

  • Co-chair’s Opening Remarks


  • DE-RISKING OF COMBINATION IMMUNOTHERAPIES PLENARY SESSION

  • 8:30 am

  • Preclinical Models for Rational Combinations


  • Immune Monitoring to Determine Efficacy of Combination Immunotherapy


  • Rational Combinations of Targeted and Immunotherapy


  • Morning Networking Break


  • Epigenetic Therapy Combinations with Immunotherapy


  • Use of Master Protocols: Basket Trials and Umbrellas


  • Prioritizing Combinations using a Human Phenotypic Model for Drug Development

  • 12:30 pm

  • Lunch


  • IMMUNO RESISTANCE – DRIVERS FOR COMBINATION THERAPY

  • 1:30 pm

  • Jak2 Mutations & Array of Responders and Non-responders to Immunotherapy


  • Mutations and Sensitivity & Resistance to Immunotherapy


  • Resistance Mechanisms for Immune Checkpoint Therapy


  • Immuno Resistance and Beta2 Microglobulin Mutations

  • 3:45 pm

  • Afternoon Break


  • NOVEL TECHNOLOGIES AND EMERGING BIOMARKERS PLENARY SESSION

  • 4:30 pm

  • Biomarker Standardization


  • Predictive Relationships Between TCR Repertoires and Efficacy


  • Using Next Gen Sequencing for Selecting Patients for Combination Immunotherapy Trials


  • Multiplexing IHC Assays


  • Different Platforms to make Bi-Specific Antibodies


  • Quickfire Presentations

  • 6:30 pm

  • Networking Reception

2017 Agenda

  • 8:30 am

  • Registration & Breakfast

  • 9:00 am

  • Co-chair’s Opening Remarks


  • CLINICAL COMBINATION IMMUNOTHERAPY PLENARY SESSION

  • 9:15 am

  • Emerging Key Combinations with Pembrolizumab in Late Stage Development


  • Combination Immunotherapy for Lung Cancer


  • Immune Targeting in Gastrointestinal (GI) Malignancies


  • Morning Networking Break


  • Combination Immunotherapy in Renal Cell Carcinoma


  • Combination Immunotherapy for Metastatic Bladder Cancer


  • Hematology Data for Combinations


  • CPI444 Clinical Activity and Translational Insights into a Novel Checkpoint Pathway

  • 12:15 pm

  • Lunch


  • BUSINESS ASPECTS FOR COMBINATION IMMUNOTHERAPY PLENARY SESSION

  • 1:15 pm

  • Novel Paradigms for Academic/Industry Partnerships


  • Small Biotech IO Combination Models & Trial Designs


  • PANEL: Partnerships and Deals between pharma and small biotechs to enable codevelopment of combinations


  • Additional Topics TBD

  • 3:15 pm

  • Afternoon Break


  • CLINICAL MANIFESTATIONS OF IMMUNOLOGICAL TOXICITIES

  • 3:30 pm

  • Unifying Treatment Algorithms for Immunological Toxicity


  • Toxicity of Checkpoint Modulating Drugs Across the Spectrum


  • Late Onset of Toxicities after Checkpoint Modulation


  • Updates on CD19 CAR Toxicities and How They are Managing Them with Future Combinations


  • Updates on BCMA CAR Toxicities

  • 5:15 pm

  • End of Conference